Neuron23 vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
$96.5M Series D (2025); NEU-411 LRRK2 inhibitor in Phase 2 NEULARK trial for early Parkinson's disease.
About
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. The company combines advances in human genetics with AI-based drug discovery and biomarker platforms to identify novel molecular targets and advance therapies for conditions with high unmet medical need. Its lead program, NEU-411, is a brain-penetrant, potent, and selective LRRK2 inhibitor targeting early Parkinson's disease.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.